ERBB2 and endometrial serous adenocarcinoma: Lastly, Erickson et al., 2020 [41] reported HER2-positive tumours to have worse progression-free survival, recurrence, and overall survival, after a median follow-up of 50 months in 169 stage I uterine serous carcinomas.